Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Anton Hagenbeek, MD PhD, Josée M Zijlstra, MD, Wouter J Plattel, MD, Franck Morschhauser, MD, Petronella J Lugtenburg, MD PhD, Pauline Brice, MD, Martin Hutchings, MD, Thomas Gastinne, MD, Roberto D Liu, Coreline N Burggraaf, MD, Marcel Nijland, MD, Sanne H Tonino, MD PhD, Harm van Tinteren, MSc, Marta I Lopez Yurda, MSc, Marie José Kersten, MD PhD

Blood (2018) 132 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2018-99-112235

Published: 2018

Journal Articles

EBV-Specific CD8 + T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia

Tom Hofland, Iris de Weerdt, Sanne Terpstra, Ester B.M. Remmerswaal, PhD, Ineke J.M. ten Berge, MD PhD, Arnon P. Kater, MD PhD, Sanne H. Tonino, MD PhD

Blood (2015) 126 (23): 1723.

https://doi.org/10.1182/blood.V126.23.1723.1723

Published: 2015

Journal Articles

Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

Iris de Weerdt, Sanne Terpstra, Tom Hofland, Roeland Lameris, MD, Renee C.G. de Bruin, Mark-David Levin, MDPhD, Ester B.M. Remmerswaal, PhD, Ineke J.M. ten Berge, MD PhD, Sanne H. Tonino, MD PhD, Tanja D de Gruijl, PhD, Hans van der Vliet, MD PhD, Arnon P. Kater, MD PhD

Blood (2015) 126 (23): 2914.

https://doi.org/10.1182/blood.V126.23.2914.2914

Published: 2015

Journal Articles

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

Arnon P. Kater, MD PhD, Sanne H. Tonino, MD, PhD, Marie Jose Kersten, MD, PhD, Anton Hagenbeek, MD, PhD, Marjolein Spiering, Msc, Marinus H van Oers, MD PhD, Yan Xin, PhD, Srinivasan Ramanathan, PhD, Maria Aiello, MA, Susie Jun, MD, PhD

Blood (2013) 122 (21): 2881.

https://doi.org/10.1182/blood.V122.21.2881.2881

Published: 2013

Journal Articles

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Doreen te Raa, MD, Fernanda Pascutti, PhD, Juan J Garcia-Vallejo, PhD, Emilie Reinen, Ester B.M. Remmerswaal, René A.W. Van Lier, PhD, Eric Eldering, PhD, Marinus H.J. Van Oers, MD, PhD, Sanne H. Tonino, MD PhD, Arnon P. Kater, MD PhD

Blood (2013) 122 (21): 2862.

https://doi.org/10.1182/blood.V122.21.2862.2862

Published: 2013

NARROW

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

EBV-Specific CD8 + T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Email alerts

ASH Publications

American Society of Hematology

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

EBV-Specific CD8 + T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to γδ-T Cell Mediated Killing, Provided CLL-Derived γδ-T Cell Dysfunction Can be Reversed

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

CMV-Specific CD8 + T-CELL Function Is NOT Impaired In CLL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only